Gara Jalqabaatti › Kansarii Ovarii › Florida › Tampa
Qorannoo klinikaalii Kansarii Ovarii Tampa, FL keessatti
Qorannoo 21 Kansarii Ovarii f Tampa fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Tampa
Study of AVZO-021 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Namoota walitti qabaa jiraQorannoo ilaalaa
- Moffitt Cancer Center, Tampa
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Moffitt Cancer Center, Tampa
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Moffitt, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Moffitt Cancer Center and Research Institute, Tampa
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Moffitt Cancer Center, Tampa
Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Moffitt Cancer Center, Tampa
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Tampa General Hospital Cancer Institute, Tampa
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Moffitt Cancer Center, Tampa
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Namoota walitti qabaa jira
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
Clinical Pre-screening Protocol for Ovarian Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Moffitt Cancer Center, Tampa
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Moffitt Cancer Center, Tampa
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Moffitt Cancer Center, Tampa
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Namoota walitti qabaa jiraSadarkaa 1
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Namoota walitti qabaa jiraSadarkaa 1/2
- Moffitt Cancer Center, Tampa
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Namoota walitti qabaa jiraSadarkaa 1
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Namoota walitti qabaa jiraSadarkaa 1/2
- Moffitt Cancer Center and Research Institute, Tampa
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Namoota walitti qabaa jiraSadarkaa 2
- Moffitt Cancer Center, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Tampa
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Exelixis Clinical Site #16, Tampa
Qorannoo Kansarii Ovarii magaalota biroo keessatti
- Houston, TXQorannoo 89
- New York City, NYQorannoo 69
- Boston, MAQorannoo 61
- Los Angeles, CAQorannoo 50
- Nashville, TNQorannoo 49
- Arlington, VAQorannoo 46
- Philadelphia, PAQorannoo 44
- Columbus, OHQorannoo 39
- St. Louis, MOQorannoo 38
- Chicago, ILQorannoo 36
- San Antonio, TXQorannoo 31
- Cleveland, OHQorannoo 30
Qorannoo biroo Tampa keessatti
- Kansara Qara'a Non-Small CellQorannoo 51
- Saree OljooQorannoo 43
- Saree (Gosoota Hunda)Qorannoo 39
- Kansarii ColorectalQorannoo 34
- Leukemia Myeloidii HamaaQorannoo 29
- Kansara MetastatikiiQorannoo 29
- Dhibee QaraQorannoo 29
- Kansarii PancreasQorannoo 26
- MelanomaQorannoo 19
- Myelodysplastic SyndromesQorannoo 19
- Kansarii ProstateQorannoo 18
- Cufama OnneeQorannoo 18
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.